Vaccine

Emergent BioSolutions Buys Rival Vaccine for $2 Million

 Lansing-based Emergent BioSolutions picked up its U.S. rival’s anthrax vaccination technology for $2 million, strengthening the company’s ability to make a second anthrax vaccination.

According to excerpts from the article:

In Lansing, the acquisition of VaxGen Inc.’s vaccine could add a second product line at a new plant.

Submitted by admin on Thu, 07/23/2009 - 13:40. categories [ ]